PI3K/p110δ is a novel therapeutic target in multiple myeloma
Open Access
- 2 September 2010
- journal article
- Published by American Society of Hematology in Blood
- Vol. 116 (9), 1460-1468
- https://doi.org/10.1182/blood-2009-06-222943
Abstract
In this study, we demonstrate expression and examined the biologic sequelae of PI3K/p110δ signaling in multiple myeloma (MM). Knockdown of p110δ by small interfThis publication has 47 references indexed in Scilit:
- SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERKBlood, 2009
- Autophagy: A Novel Mechanism of Synergistic Cytotoxicity between Doxorubicin and Roscovitine in a Sarcoma ModelCancer Research, 2008
- Characterization of structurally distinct, isoform-selective phosphoinositide 3′-kinase inhibitors in combination with radiation in the treatment of glioblastomaMolecular Cancer Therapeutics, 2008
- The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemiaBlood, 2007
- Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation patternProceedings of the National Academy of Sciences of the United States of America, 2007
- Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targetsNature Reviews Cancer, 2007
- Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomibBlood, 2006
- Interleukin-6 activates phosphoinositol-3′ kinase in multiple myeloma tumor cells by signaling through RAS-dependent and, separately, through p85-dependent pathwaysOncogene, 2004
- Essential Role of Caveolae in Interleukin-6- and Insulin-like Growth Factor I-triggered Akt-1-mediated Survival of Multiple Myeloma CellsPublished by Elsevier BV ,2003
- The Phosphoinositide 3-Kinase PathwayScience, 2002